![Tian Zhang, MD, MHS(@TiansterZhang) 's Twitter Profileg](https://pbs.twimg.com/profile_images/1296562199218081793/ORO-FZyU_200x200.jpg)
Tian Zhang, MD, MHS
@TiansterZhang
I treat & research GU cancers @UTSW Dallas. Columbia/Harvard Med/Duke alum; Mom & wife Tweets=my opinions ASCO: https://t.co/Whk29PATXe
ID:2171015611
02-11-2013 22:06:07
8,1K Tweets
7,6K Followers
963 Following
Follow People
![Tian Zhang, MD, MHS(@TiansterZhang) 's Twitter Profile Photo Tian Zhang, MD, MHS(@TiansterZhang) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1296562199218081793/ORO-FZyU_200x200.jpg)
Join our #WomeninRCC webinar on July 17! Grateful to Lynn Schuchter for her time & wisdom. Will also have 3 early career women recap their #ASCO24 presentations.
Thanks Kidney Cancer for organizing!
Register here:
bit.ly/3VofzVm
![Tian Zhang, MD, MHS(@TiansterZhang) 's Twitter Profile Photo Tian Zhang, MD, MHS(@TiansterZhang) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1296562199218081793/ORO-FZyU_200x200.jpg)
![ASCO(@ASCO) 's Twitter Profile Photo ASCO(@ASCO) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1768689771818188801/VfrMhROq_200x200.png)
![Tian Zhang, MD, MHS(@TiansterZhang) 's Twitter Profile Photo Tian Zhang, MD, MHS(@TiansterZhang) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1296562199218081793/ORO-FZyU_200x200.jpg)
Patients & physicians together — Laura Esfeller Katie Coleman Dena Battle — you are the real heroes advocating for patients here w/ us & those who have left our 🌍. We do what we do because of you.
Awesome we now have survivors in #kidneycancer to lend 1st hand advocacy. 💖
![Rafeh Naqash, MD(@thenasheffect) 's Twitter Profile Photo Rafeh Naqash, MD(@thenasheffect) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1726772913469046792/UgsMoHr0_200x200.jpg)
Was fortunate to be a small part of #ASCO24 with ⭐️ Jarushka Naidoo Tian Zhang, MD, MHS Melina Marmarelis Charu Aggarwal, MD, MPH, FASCO Patrick Forde Lecia Sequist, MD, MPH and many others including @asco leadership. Looking forward to next year under Dr. Zon ASCOPres and Erika Hamilton, MD!
![Tian Zhang, MD, MHS(@TiansterZhang) 's Twitter Profile Photo Tian Zhang, MD, MHS(@TiansterZhang) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1296562199218081793/ORO-FZyU_200x200.jpg)
Always eloquent from the man/the legend Toni Choueiri, MD — #kidneycancer biomarkers from #CLEAR ASCO #ASCO24
![OncoAlert(@OncoAlert) 's Twitter Profile Photo OncoAlert(@OncoAlert) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1215669650333323266/z8agvcHA_200x200.jpg)
Dear Colleagues at #ASCO24
An honor to introduce our OncoAlert 🚨faculty and Heart and Soul of the Network Toni Choueiri, MD 🇺🇸of Dana-Farber who discusses Biomarker Analysis of CLEAR trial in #KidneyCancer
Sumanta K. Pal, MD, FASCO Cristiane D Bergerot Daniel Heng Andrea Apolo, M.D. Toni Choueiri, MD Petros Grivas
![Neeraj Agarwal, MD, FASCO(@neerajaiims) 's Twitter Profile Photo Neeraj Agarwal, MD, FASCO(@neerajaiims) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1179881343674654720/uWRt5o3R_200x200.jpg)
Fantastic presentation by Dr. Shilpa Gupta 👉pts reported outcomes from ph3 EV-302 trial ASCO #ASCO24 👉Rx with enfortumab+pembro significantly improved OS without adversely affecting QOL, pain or functioning. Tom Powles Bladder Cancer Advocacy Network OncoAlert Umang Swami
![Neeraj Agarwal, MD, FASCO (@neerajaiims) on Twitter photo 2024-06-03 13:26:47 Fantastic presentation by Dr. @shilpaonc 👉pts reported outcomes from ph3 EV-302 trial @ASCO #ASCO24 👉Rx with enfortumab+pembro significantly improved OS without adversely affecting QOL, pain or functioning. @tompowles1 @BladderCancerUS @OncoAlert @umangtalking Fantastic presentation by Dr. @shilpaonc 👉pts reported outcomes from ph3 EV-302 trial @ASCO #ASCO24 👉Rx with enfortumab+pembro significantly improved OS without adversely affecting QOL, pain or functioning. @tompowles1 @BladderCancerUS @OncoAlert @umangtalking](https://pbs.twimg.com/media/GPJuuWTWIAAE8U_.jpg)
![Tom Powles(@tompowles1) 's Twitter Profile Photo Tom Powles(@tompowles1) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1206581214284537856/9PE8of4J_200x200.png)
![Tanya Dorff(@TDorffOnc) 's Twitter Profile Photo Tanya Dorff(@TDorffOnc) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/906610438686814208/wfd2tyu__200x200.jpg)
Better results with ipi/nivo in biomarker selected population of #prostatecancer . 40% response but also 40% grade 3+ diarrhea with higher dose ipi. Zang et al reported 50% response with pembro in hi TMB (JAMA Onc 2024). ICI clearly benefits select pts w/mCRPC
![Tanya Dorff (@TDorffOnc) on Twitter photo 2024-06-03 19:05:27 Better results with ipi/nivo in biomarker selected population of #prostatecancer. 40% response but also 40% grade 3+ diarrhea with higher dose ipi. Zang et al reported 50% response with pembro in hi TMB (JAMA Onc 2024). ICI clearly benefits select pts w/mCRPC Better results with ipi/nivo in biomarker selected population of #prostatecancer. 40% response but also 40% grade 3+ diarrhea with higher dose ipi. Zang et al reported 50% response with pembro in hi TMB (JAMA Onc 2024). ICI clearly benefits select pts w/mCRPC](https://pbs.twimg.com/media/GPK8PV5XsAA2HYs.jpg)
![Tian Zhang, MD, MHS(@TiansterZhang) 's Twitter Profile Photo Tian Zhang, MD, MHS(@TiansterZhang) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1296562199218081793/ORO-FZyU_200x200.jpg)
Excited to see you take on the scientific planning committee leadership for next year’s meeting, Erika Hamilton, MD!!
![Tian Zhang, MD, MHS(@TiansterZhang) 's Twitter Profile Photo Tian Zhang, MD, MHS(@TiansterZhang) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1296562199218081793/ORO-FZyU_200x200.jpg)
![Toni Choueiri, MD(@DrChoueiri) 's Twitter Profile Photo Toni Choueiri, MD(@DrChoueiri) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/693093012025561088/tgX3Norh_200x200.jpg)
Masterful presentation by Shilpa Gupta discussing patient-reported outcomes phase III trial of EV+P vs. PBC in untreated la/mUC:
Patients in the EV+P group have improved survival compared with PBC without detriment to GHS/QoL, pain, or functioning!
Tom Powles Cleveland Clinic
![Toni Choueiri, MD (@DrChoueiri) on Twitter photo 2024-06-03 13:24:22 Masterful presentation by @shilpaonc discussing patient-reported outcomes phase III trial of EV+P vs. PBC in untreated la/mUC: Patients in the EV+P group have improved survival compared with PBC without detriment to GHS/QoL, pain, or functioning! @tompowles1 @ClevelandClinic Masterful presentation by @shilpaonc discussing patient-reported outcomes phase III trial of EV+P vs. PBC in untreated la/mUC: Patients in the EV+P group have improved survival compared with PBC without detriment to GHS/QoL, pain, or functioning! @tompowles1 @ClevelandClinic](https://pbs.twimg.com/media/GPJuLIfWgAAQpyp.jpg)